News

Cytokinetics Reports Second Quarter 2025 Financial Results and Provides Business Update
Regulatory Reviews of Aficamten for Obstructive HCM Progressing in U.S., E.U. and China; Late-Cycle Meeting with U.S. FDA ...
TMCnet4h
Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025
PD-1 Inactivated TIL Cell Therapy (IOV-4001): Results are anticipated in the second half of 2025 from the Phase 2 efficacy portion of the IOV-GM1-201 trial in previously treated advanced melanoma.
MyChesCo on MSN21h
Madrigal Reports $212.8M in Q2 Rezdiffra Sales, Expands Global Pipeline and Secures $500M Financing
CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) reported strong second-quarter results, led by surging ...
Physicians Committee for Responsible Medicine14h
Physicians Committee Calls on MAHA to Warn About Risks of Animal Products and to Take a Nuanced Approach on Processed Foods
As the Make America Healthy Again Commission prepares to release the follow-up to the Make Our Children Healthy Again ...
US FDA moves to boost domestic drug manufacturing after Trump push
The U.S. Food and Drug Administration on Thursday announced a new program to speed up construction and review of drug ...
American Hospital Association4h
FDA announces new program to boost domestic drug manufacturing
The Food and Drug Administration Aug. 7 announced a new program to help improve the domestic pharmaceutical supply chain by ...
CRH sees US market for supplementary cementitious materials doubling by 2050
CRH expects the market for supplementary cementitious materials (SCM), a low-carbon alternative to cement, to double in the United States by 2050, the head of the largest building materials producer ...